Video

Dr. Eileen O'Reilly on Factors to Consider in Pancreatic Cancer Treatment

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

Oncologists will often take into consideration patients’ preference with factors such ability to come in often for infusions, fear of alopecia, and costs of care, which is becoming increasingly prevalent in the conversation regarding treatment planning, O’Reilly says.

Comorbidities and performance status are also considered, and as more therapies for pancreatic become available, more oncologists are questioning whether second-line therapies should be considered when choosing the initial treatment.

<<<

View more from the 2016 World Congress on GI Cancer

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Paul G. Richardson, MD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer
Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer
Richard T. Lee, MD, Cherng Family Director’s Chair, Center for Integrative Oncology, medical director, clinical professor, Supportive & Integrative Medicine, Department of Supportive Care Medicine, City of Hope
Rachna T. Shroff, MD, MS
Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL
Daneng Li, MD, associate professor, Department of Medical Oncology & Therapeutics Research, and co-director, Neuroendocrine Tumor Program, City of Hope
Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer